Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

SPONSORED CONTENT: Industry-supported content is provided by IASLC as a sponsor benefit.
The content has not been reviewed by IASLC and does not necessarily reflect the views or positions of IASLC.

SPONSORED CONTENT: Industry-supported content is provided by IASLC as a sponsor benefit. The content has not been reviewed by IASLC and does not necessarily reflect the views or positions of IASLC.

Join Bayer at WCLC 2026: Connecting Science, Clinical Practice, and Patient-Centered Care in HER2-Mutant NSCLC

August 19, 2026

Estimated Read Time:

1–2 minutes

1. Bayer-sponsored symposium

From Evidence to Early Adoption: A Comprehensive Approach to the Management of HER2-Mutant NSCLC

Saturday, September 12 | 3:00 p.m. – 4:00 p.m. KST | Room 103, Grand Ballroom, 1F

As our understanding of HER2-mutant NSCLC continues to evolve, this symposium brings together expert perspectives on the clinical significance of HER2 in NSCLC, what it means for patients, and the emerging evidence shaping the future of care.

Symposium faculty:

Prof. Tony Mok (Chair), The Chinese University of Hong Kong

Dr. Soo-Ryum (Stewart) Yang, Memorial Sloan Kettering Cancer Center

Marcia Horn, ICAN, International Cancer Advocacy Network

2. Meet the Expert series

Expert Perspectives on HER2-mutant NSCLC at WCLC 2026

Join Bayer at WCLC 2026 for a series of Meet the Expert sessions exploring key aspects of care for patients with HER2-mutant NSCLC.

Whether you are looking to deepen your understanding of biomarker testing, explore treatment decision-making in HER2-mutant NSCLC, or gain practical management insights, these focused expert-led discussions offer valuable perspectives grounded in real-world clinical experience.

Visit the Bayer booth (#123) at WCLC 2026 to attend the live sessions. The sessions will also be recorded and shared post-congress.

Schedule

Precision in practice: Identifying the HER2-mutant NSCLC patient

Speaker: Dr. Helena Yu
Date & time: Sunday September 13, 1:00 p.m. – 1:15 p.m. KST

Explore practical considerations for recognizing and identifying patients with HER2-mutant NSCLC and the role of biomarker testing in supporting informed treatment decisions.

Decisions in practice: The role of sevabertinib in HER2-mutant NSCLC

Speaker: Dr. Herbert Loong
Date & time: Sunday September 13, 3:00 p.m. – 3:15 p.m. KST

Hear expert perspectives on the evolving treatment landscape and considerations for incorporating sevabertinib into clinical practice for patients with HER2-mutant NSCLC.

Plus more…

These initiatives are developed and offered by Bayer. This is not an official program of the International Association for the Study of Lung Cancer.

MA-M_SEV.-KR-0013 | July 2026